5-azacytidine
Recurrent Non-Hodgkin Lymphoma
National Cancer Institute (NCI)Phase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Recurrent Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab University of Pittsburgh | Phase 2/3 | BBB |
Fludarabine Marcela V. Maus, M.D.,Ph.D. | Phase 3 | BBB |
Cediranib Mayo Clinic | Phase 2 | BB |
Tazemetostat SWOG Cancer Research Network | Phase 2 | BB |
Ipilimumab OHSU Knight Cancer Institute | Phase 2 | BB |
View all 21 →
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →